Noven Announces Availability of Briefing Documents For Daytrana™ Advisory Committee Meeting

-- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) confirmed today that the U.S. Food and Drug Administration (FDA) has posted briefing documents on its website ( for the Psychopharmacologic Drugs Advisory Committee meeting to be held December 2, 2005 relating to Daytrana™ (methylphenidate transdermal system).

Daytrana™, licensed globally to Shire Pharmaceuticals Group plc, is an investigational transdermal patch designed for once-daily use to treat attention deficit hyperactivity disorder (ADHD) in children aged 6 to 12 years.

Documents posted on the FDA website include materials submitted by Noven and Shire as well as FDA materials.

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Noven's prescription patches are sold in over 30 countries, and a range of new patches are being developed in collaboration with Shire Pharmaceuticals Group plc, Novartis Pharma AG, P&G Pharmaceuticals, Endo Pharmaceuticals Inc. and others. See for additional information.

Joseph C. Jones
Vice President – Corporate Affairs